Form 4: Spyre Therapeutics Director Receives Stock Option Grant

Director Mark C. McKenna was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Mark C. McKenna received a grant of 8,026 stock options for Spyre Therapeutics, Inc. (SYRE) common stock.
• The options have an exercise price of $72.51 per share.
• The grant date for these options is May 27, 2026.
• The options are scheduled to vest on the earlier of May 27, 2027, or the date of the 2027 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director's continuous service to the issuer.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent, typically following annual meeting cycles.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for mid-cap biotechnology firms.
• The one-year vesting schedule is typical for annual director equity awards.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on May 27, 2027, or the 2027 annual meeting date.

Key Dates

Keywords

Spyre Therapeutics, SYRE, Form 4, Insider Trading, Stock Options, Director Compensation